European lactase persistence genotype shows evidence of association with increase in body mass index by Kettunen, Johannes et al.
European lactase persistence genotype shows
evidence of association with increase
in body mass index
Johannes Kettunen1,2,3, , Kaisa Silander2,3, Olli Saarela2, Najaf Amin5, Martina Mu ¨ller6,7,8,
Nicholas Timpson9, Ida Surakka2,3, Samuli Ripatti2,3, Jaana Laitinen10, Anna-Liisa Hartikainen11,
Anneli Pouta11,12,P a ¨ivi Lahermo4, Verneri Anttila1, Satu Ma ¨nnisto ¨2, Antti Jula2, Jarmo Virtamo2,
Veikko Salomaa2, Terho Lehtima ¨ki13, Olli Raitakari14, Christian Gieger7, Erich H. Wichmann7,8,15,
Cornelia M. Van Duijn5, George Davey Smith6, Mark I. McCarthy16,17,
Marjo-Riitta Ja ¨rvelin18,19,20,21, Markus Perola2,3,22 and Leena Peltonen1,2,3,22,23
1Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1HH, UK,
2Department of Chronic Disease Prevention, National Institute for Health and Welfare FIN-00251, Helsinki, Finland,
3FIMM, Institute for Molecular Medicine Finland and
4Finnish Genome Center, Institute for Molecular Medicine
Finland, University of Helsinki, FIN-00251 Helsinki, Finland,
5Department of Epidemiology, Erasmus University
Medical Center (MC) Rotterdam, 3000 CA, Rotterdam, The Netherlands,
6Department of Medicine I, Klinikum
Grosshadern, 81377 Munich, Germany,
7Helmholtz Zentrum Mu ¨nchen, German Research Center for Environmental
Health, Institute of Epidemiology, 85764 Neuherberg, Germany,
8Institute of Medical Informatics, Biometry and
Epidemiology, Chair of Epidemiology, Ludwig-Maximilians-Universita ¨t, 81377 Munich, Germany,
9MRC Centre for
Causal Analyses in Translational Epidemiology, University of Bristol, Bristol BS8 2BN UK,
10Finnish National Institute
of Occupational Health, FIN-90220 Oulu, Finland,
11Department of Clinical Sciences/Obstetrics and Gynecology,
University of Oulu, FIN-90014 Oulu, Finland,
12National Public Health Institute and University of Oulu, FIN-90101
Oulu, Finland,
13Department of Clinical Chemistry, Tampere University Hospital and University of Tampere, FIN-
33521 Tampere, Finland,
14Department of Clinical Physiology, University of Turku and Turku University Central
Hospital, FIN-20521 Turku, Finland,
15Klinikum Grosshadern, Ludwig Maximilians University, 81377 Munich,
Germany,
16Oxford Centre for Diabetes, Endocrinology and Metabolism, Headington, Oxford OX3 7LJ, UK,
17The
Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, UK,
18Department of Epidemiology
and Public Health, Imperial College London, London W2 1PG, UK,
19Institute of Health Sciences, University of Oulu,
FIN-90014 Oulu, Finland,
20Department of Child and Adolescent Health, National Public Health Institute, FIN-90101
Oulu, Finland,
21Biocenter Oulu, University of Oulu, FIN-90014 Oulu, Finland,
22Department of Medical Genetics,
University of Helsinki, FIN-00014 Helsinki, Finland and
23The Broad Institute of MIT and Harvard, Boston, MA 02142,
USA
Received July 2, 2009; Revised December 4, 2009; Accepted December 14, 2009
The global prevalence of obesity has increased signiﬁcantly in recent decades, mainly due to excess calorie
intake and increasingly sedentary lifestyle. Here, we test the association between obesity measured by body
mass index (BMI) and one of the best-known genetic variants showing strong selective pressure: the func-
tional variant in the cis-regulatory element of the lactase gene. We tested this variant since it is presumed
to provide nutritional advantage in speciﬁc physical and cultural environments. We genetically deﬁned
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Advance Access published on December 16, 2009lactase persistence (LP) in 31 720 individuals from eight European population-based studies and one family
study by genotyping or imputing the European LP variant (rs4988235). We performed a meta-analysis by
pooling the b-coefﬁcient estimates of the relationship between rs4988235 and BMI from the nine studies
and found that the carriers of the allele responsible for LP among Europeans showed higher BMI (P 5
7.9 3 10
25). Since this locus has been shown to be prone to population stratiﬁcation, we paid special atten-
tion to reveal any population substructure which might be responsible for the association signal. The best
evidence of exclusion of stratiﬁcation came from the Dutch family sample which is robust for stratiﬁcation.
In this study, we highlight issues in model selection in the genome-wide association studies and problems in
imputation of these special genomic regions.
INTRODUCTION
The lactase gene [LCT (MIM 603202)] is expressed in the
intestinal epithelial cells and its protein product contributes
to carbohydrate metabolism via digestion of the milk sugar
lactose. The activity of the lactase enzyme in intestinal cells
normally declines during childhood. Individuals with lactase
non-persistence show varying degrees of abdominal pain, diar-
rhoea, bloating and gas formation after consumption of
lactose-containing foods, in particular milk and other non-
fermented dairy products. Molecular studies of lactose
intolerance led to the identiﬁcation of speciﬁc variations in a
cis-regulatory element of the LCT gene resulting in lactase
persistence (LP) which is an autosomal dominant condition
(MIM 223100). The LP single-nucleotide polymorphism
(SNP) most common among individuals of European descent
(C/T-13910, rs4988235) was ﬁrst identiﬁed by Enattah et al.
(1) in Finnish lactose intolerance families. The T allele corre-
lated perfectly with the LP phenotype of intestinal cells and
functional studies have shown that the T allele is associated
with the disrupted down-regulation of the LCT gene during
childhood (2,3). The enhancer function of this mutation has
also been shown in vitro (4,5). Subsequently, this region has
yielded a spectrum of variants, some showing population
speciﬁcity (6–8). These variants have been under strong posi-
tive selection regionally and seem to reﬂect independent
events of cattle domestication, as exempliﬁed by the two
different allelic backgrounds of the Arabic and European LP
alleles (6,9). The European LP allele has been associated
with higher milk consumption in Finnish, Estonian and
Austrian populations, one of which being the Finnish YF
sample used in this study (10–15).
We hypothesized that since lactase non-persistent individ-
uals are on a more restricted diet when compared with the
LP individuals, this may have an impact on body mass
index (BMI) and/or height. Lactose-containing dairy products
are often high in energy content potentially increasing daily
calorie intake, and for the lactase non-persistent, they may
cause diarrhoea which can prevent the absorption of nutrients.
Further, milk is rich in calcium, required for skeletal growth.
BMI is calculated as weight in kilograms divided by the
square of height in meters. BMI has been studied extensively
due to the health effects of obesity and its relative ease of
measurement. Excessive weight increases the risk of type II
diabetes, coronary artery disease and hypertension, and is
associated with many forms of cancer along with adverse
social and psychological consequences (16,17). The need for
more effective clinical strategies has become evident with
the increasing prevalence of obesity in recent years (18).
This has put pressure on genetic studies to ﬁnd variants
responsible for differences in response to positive energy
balance. Recent genome-wide association studies (GWASs)
have been able to show association between BMI and
genetic variants in a total of 13 genomic regions (19–22). In
this study, we show the association between genetically
deﬁned LP and BMI.
RESULTS
The effect of LP was evaluated in ﬁve Finnish representative
population cohorts, all non-ascertained for BMI or height:
The North Finland Birth Cohort 1966 (NFBC 1966), The
Health 2000 Health Examination Survey (Health2000), The
Cardiovascular Risk of Young Finns Study (YF), the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention (ATBC) study
and the FINRISK which is a cross-sectional population
survey targeting coronary risk factors collected every
5 years. The cohort-speciﬁc analyses were performed on cor-
rected phenotype comparing the C-13910 allele homozygotes
(lactase non-persistent, CC genotypes) against T-13910 allele
carriers (LP, CT and TT genotypes) using linear regression.
There was evidence for association with BMI and the LP in
the NFBC 1966 (n ¼ 5498, C allele frequency ¼ 0.39,
b ¼ 20.11, P ¼ 0.002) and in ATBC cohorts (n ¼ 2126, C
allele frequency ¼ 0.40, b ¼ 20.12, P ¼ 0.04) and the same
direction of association in Health2000 (n ¼ 5320, C allele
frequency ¼ 0.42, b ¼ 20.06, P ¼ 0.10), YF (n ¼ 2165, C
allele frequency ¼ 0.42, b ¼ 20.04, P ¼ 0.51) and
FINRISK (n ¼ 2265, C allele frequency ¼ 0.45, b ¼ 20.09,
P ¼ 0.09) cohorts. Table 1 summarizes the cohort-speciﬁc
analyses.
The CC genotype was associated with decreased BMI com-
pared with CT/TT genotypes in the meta-analysis of 17 374
Finns (b ¼ 20.08, P ¼ 1.5   10
25). The individuals carrying
the LP allele had 0.3 kg/m
2 higher BMI than the non-persistent
individuals which corresponds to 1 kg for an average person.
The single study results from linear regression and the
meta-analyses are summarized as a forest plot (Fig. 1).
We also performed a sex-speciﬁc meta-analysis and found
that males (n ¼ 9739, b ¼ 20.09, P ¼ 1.6   10
24) had some-
what higher effect estimate in the model than females (n ¼
7635, b ¼ 20.06, P ¼ 0.02), but there was no robust statisti-
cal evidence of a gender difference (P ¼ 0.6).
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cohorts, NFBC 1966 (n ¼ 4911) and Health2000 (n ¼ 2145,
metabolic syndrome case–control sample). The ﬁrst 14 eigen-
vectors from the principal components analysis of the GWA
SNP panel explained relatively the largest proportion of the
variance of the principal components in the NFBC 1966;
therefore, we tested for the correlation of BMI between
these eigenvectors in both genome-wide SNP data sets. We
used linear regression to evaluate evidence of correlation
between the eigenvectors and BMI. No correlation was
found in either NFBC 1966 or the Health2000 (P . 0.05).
We tested for the correlation of LP and eigenvectors using
logistic regression since the response variable was dichoto-
mous. The 5th (P ¼ 0.02) and 10th (P ¼ 0.01) principal
components showed most evidence of correlation with LP in
NFBC 1966, and the 2nd (P ¼ 0.02), 7th (P ¼ 0.008) and
12th (P ¼ 0.008) eigenvectors with LP in Health2000. Includ-
ing these eigenvectors as covariates in the linear regression did
not change association between BMI and LP in the NFBC
1966 data or in the Health2000 subsample. In NFBC 1966,
the linear regression b changed marginally (b ¼ 20.12, P ¼
0.003), and in the Health2000 subsample, the effect size
remained the same (b ¼ 20.13, P ¼ 0.03). Since the
Health2000 subsample was ascertained for metabolic syn-
drome, we tested for the effect in both cases and controls sep-
arately, and found the linear regression b to be equal in both
groups.
Frayling et al. (19) have shown that the FTO rs9939609 A
allele is positively associated with BMI. We had both LCT and
FTO genotypes available in NFBC 1966 cohort for 4955 indi-
viduals. The difference between FTO AA and TT homozy-
gotes was 0.5 kg/m
2. We compared the proportion of
variance in BMI explained by FTO and the proportion
explained by LP. The additive model (n ¼ 4955, P ¼ 6.7  
10
24) of the FTO gene association was found to explain
0.2% of the variance in BMI in the NFBC 1966 cohort. Simi-
larly, the dominant effect of LP was found to account for 0.2%
of the variance in BMI in this cohort.
We tested for the association with height and LP marker but
we did not ﬁnd evidence of a meaningful association in the
meta-analysis in Finns (n ¼ 17 374, b ¼ 20.004, P ¼ 0.41).
We also performed a weight analysis which—as expected,
given the association with BMI but lack of association with
height—demonstrated robust association (n ¼ 17 374,
b ¼ 20.08, P ¼ 1.4   10
25). Both height and weight ana-
lyses were performed in the same way as the BMI analyses.
Since the initial GWASs have not identiﬁed this association
in the LCT region, we tested the effect of using an additive
model in the analyses instead of the correct dominant model
and combined the results with meta-analysis. The additive
model decreased the association (P ¼ 0.001) compared with
the dominant model (P ¼ 1.5   10
25). We simulated the
size of the power decrease resulting from using the incorrect
Table 1. Cohort-speciﬁc results
n (males/females) Results
LP prevalence (%) b SE P-value
NFBC 1966 5498 (2636/2862) 85 20.11 0.04 0.002
ATBC 2126 (2126/0) 84 20.12 0.06 0.04
FINRISK 2265 (1555/710) 80 20.09 0.05 0.09
Health2000 5320 (2437/2883) 82 20.06 0.03 0.10
YF 2165 (985/1180) 83 20.04 0.06 0.51
BWHHS 3109 (0/3109) 94 20.06 0.07 0.40
ERF 2104 (909/1195) 90 20.08 0.06 0.16
Rotterdam 5689 (3320/2369) 91 20.02 0.05 0.69
KORA S3 1578 (783/795) 87 20.001 0.07 0.99
KORA S4 1755 (859/896) 87 0.08 0.06 0.24
n, number of individuals; SE, standard error; LP, lactase persistence determined by the frequency of T-13910 allele carriers, b (SE) are from the association analysis
between standardized BMI and LP (rs4988235 CC against CT/TT genotypes). The nationwide Finnish cohort analyses of Health2000, YF and FINRISK were
corrected for region of residence(Southwest,East and Oulu region), age and sex effects in Health2000 cohort and FINRISKcohort, with sex in NFBC 1966 cohort,
with age in ATBC cohort, with age and birth place coordinates in BWHHS, with sex and age in ERF study (family-based sample), with age, sex and ﬁrst 10
principal components in Rotterdam and KORA studies. Outliers deviating more than three standard deviations were removed from the analyses.
Figure 1. The forest plot of the linear regression analyses and meta-analyses.
Human Molecular Genetics, 2010, Vol. 19, No. 6 1131additive model instead of the correct dominant model through
bootstrapping. The results of this power comparison are sum-
marized in Table 2.
We performed a dominance deviation test from additivity in
each cohort separately and pooled the b-estimates with
meta-analysis. The dominance term suggested that we could
reject the additive model (P ¼ 0.001, b ¼ 0.047).
The linear regression analysis of the British Women’s Heart
and Health Study (BWHHS) showed that the difference
between the LP and lactase non-persistent was 0.30 kg/m
2
(n ¼ 3109, b ¼ 20.06, P ¼ 0.4, C allele frequency ¼ 0.25)
which is in line with our ﬁnding in the Finnish population
but underpowered due to smaller sample size. The Dutch
analysis was performed with the Erasmus Rucphen Family
(ERF) study with extended pedigrees and Rotterdam study.
The effect size estimate from the family data was again in
line with the Finnish and British data (b ¼ 20.082, n ¼
1952, P ¼ 0.16, C allele frequency ¼ 0.32) but the population-
based Rotterdam study sample did not provide evidence for
association (b ¼ 20.02, n ¼ 5745, P ¼ 0.69, C allele
frequency ¼ 0.29) and showed smaller effect size. The
German analysis was performed with KORA S3 and KORA
S4 study samples. The effect size was not in the same direction
in the combined KORA samples (b ¼ 0.04, n ¼ 3333, P ¼
0.20, C allele frequency ¼ 0.36). We combined the effect
sizes of non-Finnish samples in meta-analysis (b ¼ 20.019,
n ¼ 14 346, P ¼ 0.24) which did not prove to be signiﬁcant.
Since we had the rs4988235 genotyped for individuals in
Health2000 subsample and NFBC 1966 and additionally we
had genome-wide SNP data, we were able to impute the
marker and compare the imputed genotypes with genotyped
ones. The imputation quality score was 0.91 and r
2 was
0.81. The phenotype-deﬁning C/C genotype had 23% discor-
dance between the imputed versus genotyped calls. Of the
1060 C/C calls in the genotyped data, 245 were not deﬁned
C/C in the imputed data. In 15 cases, the imputation gave C/
C genotype where the genotyped individuals had C/T geno-
type. In total, 11% of all calls were discordant between
imputed and genotyped data.
We combined the effect sizes of all nine cohorts in
meta-analysis. The association with BMI remained robust
(b ¼ 20.06, P ¼ 7.9   10
25) in the combined analysis of
31 720 European individuals. There was some evidence of
heterogeneity in the meta-analysis of all samples (I
2 ¼ 10),
although the Q statistics was not signiﬁcant (P ¼ 0.35).
Results of the individual study linear regression analyses and
the meta-analyses are summarized as a forest plot (Fig. 1)
and in Table 1.
DISCUSSION
In this study, we present novel evidence of association
between genetically deﬁned LP and BMI (P ¼ 7.9   10
25)
in 31 720 individuals from four European populations. The
LCT C/T-13910 marker frequency shows strong population
differences. Campbell et al. (23), sampling from an European
American population, tested for an association between height
and the C/T-13910 marker and found robust association between
the marker and height if they did not correct for the ancestral
origin of the samples. After the correction for ancestral origin,
the association was considerably attenuated, thus indicating
that the association was most likely an incidental reﬂection
of population stratiﬁcation of this variant. Similar generation
of a link between the LCT C/T-13910 marker and self-rated
health has been shown to be due to population stratiﬁcation
in a British study (24). We tested for the association with
height and the LP marker and we did not ﬁnd this marker to
be associated with height. The NFBC 1966 cohort and a
subset of the Health2000 cohort had genome-wide SNP data
available with which we could assess the effect of population
substructure. The ﬁrst two principal components describe the
geographical origin of the individuals in NFBC 1966 cohort,
as has been shown by Jakkula et al. (25). We showed that
none of the ﬁrst 14 eigenvectors had a material effect on the
association analysis in both the regional NFBC 1966 sample
and a country-wide Health2000 subsample, which strongly
suggests that the association was not due to population strati-
ﬁcation. The best evidence which would exclude the effect of
stratiﬁcation came from the ERF study from the Netherlands.
Although the QTDT (26) analyses were not signiﬁcant, the
effect size was in line with the population-based studies
which is a good indicator that the population-based results
were not due to stratiﬁcation. All ﬁve Finnish study cohorts
showed the same trend of increased BMI (heterogeneity
I
2 ¼ 0), although the association was not conventionally sig-
niﬁcant in all cohorts individually. However, after combining
the cohorts in the meta-analysis, the association was robust
(Fig. 1). We showed that the increase in BMI was mediated
through the increase in body weight (P ¼ 1.4   10
25) but
not through stature (P ¼ 0.41). The non-Finnish population
samples did not replicate the association signiﬁcantly (P ¼
0.24). The marker was genotyped in the British study which
showed similar effect size than the Finnish sample. The
cohorts which show smaller effect size have all been
imputed. In our Finnish sample, we found that the imputation
of this region proves to be difﬁcult and the erroneous geno-
types concentrate on the phenotype-deﬁning genotype. This
effect is shown in Finnish population and it is not possible
to assess whether it is the same case in our European replica-
tion cohorts. The ERF study is more robust for this kind of
error since it beneﬁts from the family structure in the imputa-
tion. Should the same phenomenon exist in the imputed
European replication samples, the effect size would be
Table 2. The results of power calculation for using the additive model instead
of correct dominant model where sample size (n ¼ 17 374), effect size
(b ¼ 20.082) and MAF (0.39) the same as the LCT variant had in combined
Finnish sample of this study
Signiﬁcance level Power (%)
Dominant model Additive model
0.05 98 83
0.01 91 63
0.001 73 35
1   10
24 51 16
1   10
25 30 7
1   10
26 16 2
1   10
27 81
5   10
28 61
1132 Human Molecular Genetics, 2010, Vol. 19, No. 6a drastic underestimate and would explain why the European
replication cohorts show smaller effect size.
We had FTO genotypes available for the NFBC 1966 cohort
and were able to compare the effect size of these two variants.
The LP variant had a similar effects size and explained a
similar proportion of variance to FTO in this cohort.
A GWAS by Meyre et al. (27) has previously shown associ-
ation in this region. They showed an association (P ¼ 9.2  
10
24) with a marker which is in LD (HapMap, r
2 ¼ 0.58,
D0 ¼ 0.80, rs2011946) with the LP variant and BMI in 135
obese adults and 794 lean adults of French origin. It is not
possible to determine whether this association was due to stra-
tiﬁcation or not. They could not show association in an inde-
pendent population-based cohort possibly because the cohort
was underpowered (n ¼ 4417). The effect in the study by
Meyre et al. was in the same direction as in our study in all
of the three tested adult cohorts. Any further comparison is
not possible since they did not have the same marker geno-
typed.
There are several possible explanations as to why the LP
association with BMI may have remained undetected in rest
of the GWA analyses. First, the functional variant is not
included in any currently used SNP arrays and the power
has been reduced due to insufﬁcient linkage disequilibrium
(LD). The recently published GWASs were genotyped either
by Affymetrix 5.0 or Illumina array which has less coverage
in this area than the HumanHap 650 array (19–22). We
found that the strongest LD (r
2) with the LCT C/T-13910 and
any marker within 500 000 bp in the HapMap CEPH (Utah
residents with ancestry from northern and western Europe)
sample included in the Illumina HumanHap 650 or Affymetrix
5.0 array was 0.78 (rs309160) (28). Second, the ﬁrst four
GWASs had used an additive model, which given the domi-
nant inheritance model of LP and based on what we show
here is inappropriate, and results in a considerable decrease
in power as shown in Table 2. The strength of evidence of
association was also reduced in our data set when the incorrect
model was used (additive P ¼ 0.001 versus dominant P ¼
1.5   10
25). Third, the imputation accuracy might be compro-
mised in this region as was shown by our Finnish sample.
Together, the incomplete tagging or inaccurate imputation
combined with the use of an inappropriate genetic model
may explain why this association has remained undetected.
Furthermore, the association of LP with milk consumption
varies between populations, being stronger in settings of inter-
mediate allele frequency than when one allele is rare (24). One
cannot reject cultural inﬂuences on milk consumption overrid-
ing the generally rather minor discomfort consequent on milk
ingestion by non-persistent individuals and lead to the expec-
tation that the association of LP genotype with BMI will be
context-speciﬁc (29). The effect size of this variant may be
large in Finland where dairy product consumption is very
common and there is a correlation with liquid dairy product
consumption and the LP variant (10,11). Further, the effect
size may have been overestimated in the initial Finnish discov-
ery sample.
The mechanism by which LP affects body composition may
be related to the more restricted diet the lactase non-persistent
individuals may choose or perhaps the negative symptoms
such as diarrhoea after using lactose-containing food products
play some role. This ﬁnding may also reﬂect the positive
selection the LP allele has been subject to in recent history.
Our study highlights the fact that the recent GWASs have
not exhaustively revealed the common variants affecting
BMI. Although explanation at a functional level is a matter
for future studies and ﬁnding is not signiﬁcant in the GWAS
established genome-wide level of signiﬁcance, we propose
that the European variant behind LP, and perhaps other var-
iants affecting the regulatory region of LCT, contributes to
human obesity.
MATERIALS AND METHODS
Study samples
Informed consent was obtained from all participants and study
was conducted according to the principles expressed in the
Declaration of Helsinki and the studies were reviewed and
accepted by local ethics committees. Table 3 shows the
cohort characteristics. More detailed description of the study
cohorts can be found at the National Biobank of Finland
website (see Web Resources) and from the University of
Turku website (YF cohort, see Web Resources). In brief, the
NFBC 1966 includes individuals born in the Northernmost
provinces of Finland with expected date of birth in 1966
who underwent a health examination at age 31. The
Health2000 was conducted in 2000 to explore the health of
the Finnish population. Our Health2000 cohort consists of
individuals aged 30 and over. The ATBC study was initially
collected to test whether a-tocopherol and b-carotene sup-
plements would reduce the incidence of lung and other
cancers. The participants were male smokers aged 50–69
years from South-western Finland. FINRISK is a cross-
sectional population survey targeting coronary risk factors col-
lected every 5 years. The current study contains individuals
recruited during years 1992 and 1997 and were selected for
cardiovascular study. The YF is a population-based prospec-
tive cohort study conducted at ﬁve university departments of
medical schools in Finland (i.e. Turku, Helsinki, Kuopio,
Tampere and Oulu), with the aim of studying the levels of car-
diovascular risk factors in children and adolescents in different
parts of the country. The latest follow-up was conducted in
2007. The present analysis included 2165 subjects with data
on height, weight and the gene variant. The study and data col-
lection protocols have been described in detail by Raitakari
et al. (30). The Health2000, YF and FINRISK participants
were collected across Finland, whereas NFBC 1966 was
sampled within the Northern region and the ATBC within
the South-western region of Finland. The same analyses
were performed in the BWHHS. Full details of the selection
of participants and measurements have been reported earlier
(31,32). Women aged 60–79 years were randomly selected
from primary care lists in 23 British towns. Women were
recognized as non-white in the BWHHS and excluded from
further analyses.
The ERF study is an extended-pedigree study (n ¼ 2700)
focused on the identiﬁcation of quantitative traits loci related
to neuropsychiatric, cardiovascular, endocrinological, ophthal-
mological and musculoskeletal disorders. The ERF sample has
been described in more detail by Aulchenko et al. (33).
Human Molecular Genetics, 2010, Vol. 19, No. 6 1133The Rotterdam study (34) is an ongoing prospective,
population-based cohort study among 7983 persons aged 55
years and older, living in Ommoord, a district of Rotterdam,
The Netherlands. The study was designed to investigate the
incidence and determinants of chronic disabling diseases.
The study is composed of an outbred ethnically homogeneous
population of Dutch Caucasian origin. Rationale and design
have been described previously. Informed consent was
obtained from each participant, and the Medical Ethics Com-
mittee of the Erasmus Medical Centre Rotterdam approved the
study. At baseline (1990–1993), all participants were inter-
viewed and underwent extensive physical examination.
These examinations were performed according to the same
protocol at the second follow-up (1997–1999).
The KORA [Cooperative Health Research in the Augsburg
Region; Wichmann et al. (35)] studies are population-based
samples from the general population living in the region of
Augsburg, Southern Germany. The KORA S3 survey (4856
subjects, response 75%) has been examined in the years
1994–1995. The KORA S4 survey was conducted in 1999–
2001. The KORA S3 and S4 samples do not overlap. The
study has been approved by the local ethical committee.
Genome-wide data are available from Affymetrix 500K
chips in KORA S3 and Affymetrix 6.0 chips in KORA S4.
Methods
In Finland, the C allele homozygosity of the LCT C/T-13910
polymorphism (rs4988235) serves as a diagnostic marker for
lactase non-persistence, whereas T homozygotes and heterozy-
gotes can be classiﬁed as LP. We tested this SNP in a set of
representative population cohorts and measured its potential
association with BMI and height. The SNP LCT C/T-13910
was genotyped using iPlex assay on the MassARRAY
System (Sequenom, San Diego, CA, USA) using standard pro-
tocols in a total of 17 374 Finnish individuals. The YF cohort
LCT C/T-13910 genotyping was performed by using the
50-nuclease assay and ﬂuorogenic, allele-speciﬁc, TaqMan
probes (Applied Biosystems, Foster City, CA, USA) and
primers, with the ABI Prism 7000 sequence detection
system (Applied Biosystems). The genotype frequencies
followed Hardy–Weinberg equilibrium (HWE) in all ﬁve
cohorts (YF, P ¼ 0.814; ATBC, P ¼ 0.84; FR, P ¼ 0.77;
NFBC, P ¼ 0.93; Health2000, P ¼ 0.54) and call rate was
.95% in all samples. BWHHS genotypes for LCT C/T-13910
(rs4988235) were generated using the KASPar chemistry
which is a competitive allele-speciﬁc PCR SNP genotyping
system using FRET quencher cassette oligos using standard
protocols. The rs4988235 marker was imputed to the ERF,
Rotterdam and KORA studies. The genetic data for ERF, the
Rotterdam study and KORA S4 was imputed using MACH
with HAPMAP rel 22 CEU build 36 as a reference (ERF
imputation, r
2 ¼ 0.94, Rotterdam imputation study, r
2 ¼
0.92, KORA S4 observed versus expected variance ¼ 0.89),
whereas KORA S3 was imputed with MACH based on
HAPMAP rel 21 build 35 (observed versus expected
variance ¼ 0.91). The genotype frequencies followed HWE
in all four non-Finnish cohorts (BWHHS, P ¼ 0.88; ERF,
P ¼ 0.23; Rotterdam study, P ¼ 0.09; KORA S3, P ¼ 0.75;
KORA S4, P ¼ 0.27).
The association analyses were performed in parallel by
three collaborating groups, hence NFBC 1966 and
Health2000 were analysed with PLINK 1.04, FINRISK,
KORA and ATBC cohorts were analysed with R, and YF
and Rotterdam study cohort with SPSS, using linear
regression. The ERF study was analysed using QTDT.
Lahti-Koski et al. (36) have shown that there are no regional
differences in BMI within Finland in males, but a slight differ-
ence in females between southern and western Finland. There-
fore, we corrected the nationwide Health2000, YF and
FINRISK analyses for the area of residence (Southwest, East
and Northern Finland). The NFBC 1966 cohort was collected
from Northern Finland and ATBC from southwest Finland,
and therefore, no regional correction was applied. The pheno-
types were corrected for age and sex effects in Health2000, YF
and FINRISK cohorts, with sex in NFBC 1966 cohort (all
31 years old) and age in ATBC cohort (all men). BMI outliers
deviating more than three standard deviations from the mean
within a cohort were removed prior to analysis, resulting in
approximately normal distribution (kurtosis and skewness
both between 21 and 1). The Rotterdam study and KORA
were corrected for sex, age and ﬁrst 10 principal components
from the genome-wide data and outliers deviating more than
four standard deviations from principal components or three
Table 3. Sex-speciﬁc cohort characteristics
Males Females
n BMI Age n BMI Age
Mean SD Mean SD Mean SD Mean SD
NFBC 1966 2636 25.2 3.6 31 0 2862 23.3 3.2 31 0
ATBC 2126 26.9 4.2 64 5 NA NA NA NA NA
FINRISK 1555 28.0 4.1 58 10 710 28.2 5.2 58 9
Health2000 2437 27.0 3.9 52 14 2883 26.7 4.9 55 16
YF 985 26.7 4.2 38 5 1180 25.4 5.1 38 5
BWHHS NA NA NA NA NA 3109 27.3 4.5 69 5
ERF 909 27.3 4.3 50 15 1195 26.4 4.9 49 15
Rotterdam 3320 26.5 3.7 70 10 2369 25.6 2.9 68 8
KORA S3 783 27.6 3.4 53 10 795 26.7 4.2 52 10
KORA S4 859 27.8 3.5 54 9 896 27.2 4.6 54 9
NA, not available; SD, standard deviation; BMI, body mass index; n, number of individuals.
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means were removed. The ERF cohort was corrected for sex
and age. The family-based analyses were performed with
QTDT (26). The association method was orthogonal associ-
ation which is very robust to stratiﬁcation. Dominance effect
was included in the analysis model.
The meta-analysis was performed by pooling the
b-estimates and standard errors from the individual studies
using the inverse variance method.
We had genome-wide SNP data (Illumina HumanHap 370)
and phenotype data available for 4911 individuals from the
NFBC 1966 cohort. Similarly, we had genome-wide SNP
data (llumina HumanHap 610) available for a subset of the
Health2000 cohort (2145 individuals) ascertained for
matched case–control study for metabolic syndrome. We
tested for hidden population substructure by performing a
principal components analysis using EIGENSOFT (37). The
imputation of the marker in these cohorts was performed
with MACH using phased HAPMAP rel 22 CEU build 36 as
a reference.
The power calculations were performed via bootstrapping.
We performed 10 000 simulations where we simulated a
sample of 17 374 individuals where the minor allele frequency
(MAF ¼ 0.39) and effect size (b ¼ 20.082) were the same as
LCT variant found in this study. Each sample was analysed
with both additive and dominant models. The simulations
were performed with R.
The dominance deviation test was performed by ﬁtting
jointly the additive term and a heterozygote indicator.
The gender interaction analysis was performed by using the
meta-analysis summary statistics. The method is described
further in a book by Hardy (38).
WEB RESOURCES
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